Patents Issued in December 29, 2020
  • Patent number: 10876131
    Abstract: DIG-303 insecticidal toxins, polynucleotides encoding such toxins, use of such toxins to control pests, and transgenic plants that produce such toxins are disclosed.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 29, 2020
    Assignee: DOW AGROSCIENCES LLC
    Inventors: Meghan L. F. Frey, Justin M. Lira, Xiaoping Xu, Ignacio Mario Larrinua, Kenneth Narva, Timothy D Hey
  • Patent number: 10876132
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with one or more nucleic acid sequence encoding insecticidal protein(s) and one or more silencing element(s). In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The molecular and breeding stacks find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 29, 2020
    Assignees: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Scott Henry Diehn, Xu Hu, Albert L. Lu, Lu Liu, James Kevin Presnail, Gary A. Sandahl, Ute Schellenberger, Gusui Wu
  • Patent number: 10876133
    Abstract: The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which is capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 29, 2020
    Assignee: California Institute of Technology
    Inventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin
  • Patent number: 10876134
    Abstract: Compositions and methods for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), also known as Juvenile Batten Disease, are provided herein. In certain embodiments the compositions include but are not limited to adeno-associated viral (AAV) constructs, including self-complementary adeno-associated viral (sc-AAV) constructs, that express the human gene CLN3 (or a CLN3 cDNA).
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: December 29, 2020
    Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, OHIO STATE INNOVATION FOUNDATION
    Inventors: Tammy Kielian, Kevin Foust
  • Patent number: 10876135
    Abstract: The present invention relates to methods to modify at least one target locus in a plant cell, comprising, providing a plant cell with one or more target loci and one or more donor loci, followed by induction of homologous recombination between homologous regions of at least one target locus and at least one donor locus by at least one rare cleaving nuclease. The present invention related also to target loci, donor loci and nuclease loci used in these methods, and plant cells, plants and plant parts comprising these target loci, donor loci, nuclease loci and/or the recombined loci.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: December 29, 2020
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Rocio Sanchez-Fernandez, Christian Biesgen, Holger Puchta, Nadine Roth, Friedrich Fauser, Michael Pacher
  • Patent number: 10876136
    Abstract: Reduced graphene oxide is produced by adding graphene oxide and electrically active bacteria to a container. After a period of time reduced graphene oxide is produced by an interaction of the electrically active bacteria and the graphene oxide. The resulting composition of matter includes reduced graphene oxide and electrically active bacteria. The resulting composition of matter can be doped with a plurality of different elements.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 29, 2020
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Shafeer Kalathil, Krishna Prasad Katuri, Amira Salman Alazmi, Pedro Miguel Costa, Pascal E. Saikaly
  • Patent number: 10876137
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: December 29, 2020
    Assignee: PRECIGEN, INC.
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Patent number: 10876138
    Abstract: A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so that the activity of enolase is reduced.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Benjamin Mijts, Christine Roche, Sayaka Asari, Miku Toyazaki, Keita Fukui
  • Patent number: 10876139
    Abstract: The present invention provides for a genetically modified host cell and related methods and materials for the biocatalytic production of an ?,?-dicarboxylic acids (DCAs) and/or mono-methyl ester derivatives of dicarboxylic acids (DCAMMEs).
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: December 29, 2020
    Assignee: The Regents of the University of California
    Inventors: Robert W. Haushalter, Jay D. Keasling
  • Patent number: 10876140
    Abstract: Provided is a method for producing PHA by a microbe with improved productivity of PHA, and a PHA-producing microbe used for the production method. A method for producing polyhydroxyalkanoic acid, the method including a step of culturing a microbe having a polyhydroxyalkanoic acid synthase gene and an inactivated gene encoding a flagellar protein to cause the microbe to produce polyhydroxyalkanoic acid. In the microbe, a lipase, a dephosphorylating enzyme, and a protein represented by the amino acid sequence of SEQ ID NO: 6 or 7 may be additionally inactivated. The microbe may be Cupriavidus necator.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 29, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Shunsuke Sato, Hisashi Arikawa, Rina Aoki
  • Patent number: 10876141
    Abstract: The present invention is directed to a novel and advantageous process for the hydrolysis of biomass which enables a thorough hydrolyzation also of recalcitrant biomass such as sugar cane straw and sugar cane bagasse.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: December 29, 2020
    Assignee: Clariant International Ltd.
    Inventors: Michael Zavrel, Markus Zehe, Joerg Bartuch, Marcus Verhuelsdonk
  • Patent number: 10876142
    Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: December 29, 2020
    Assignee: YALE UNIVERSITY
    Inventors: Dieter Söll, Caroline Aldag, Michael Hohn, Takahito Mukai
  • Patent number: 10876143
    Abstract: The present invention provides methods of synthesizing trehalose analogues; methods of detecting mycobacteria, and trehalose analogues.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 29, 2020
    Assignees: Central Michigan University, University of Maine System
    Inventors: Benjamin M. Swarts, Peter Woodruff
  • Patent number: 10876144
    Abstract: A process for determining the viability of a biological indicator includes exposing the biological indicator to a viability detection medium, the biological indicator including test microorganisms, the exposing the biological indicator to the viability detection medium producing a gaseous reaction product when one or more of the test microorganisms are viable. The presence or absence of the gaseous reaction product produced by the biological indicator combined with the viability detection medium is detected with a sensing device, the sensing device comprising an electro-mechanical sensor, wherein the presence of the gaseous reaction product indicates the presence of viable test microorganisms and the absence of the gaseous reaction product indicates the absence of viable test microorganisms. A sterilization detection device includes a container configured to contain the biological indicator, a viability detection medium, and the sensing device.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 29, 2020
    Assignee: American Sterilizer Company
    Inventors: Michael A. Centanni, Phillip P. Franciskovich
  • Patent number: 10876145
    Abstract: An aerosol collection system and method. The system includes a bio-aerosol delivery device configured to supply bioparticles in a gas stream, a moisture exchange device including a partition member coupled to the gas stream and configured to humidify or dehumidify the bioparticles in the gas stream, and an aerosol collection medium downstream from the moisture exchange device and configured to collect the bioparticles. The method includes delivering bioparticles in a gas stream, humidifying or dehumidifying the bioparticles in the gas stream by transport of water across a partition member and into a vapor phase of the gas stream, and collecting the bioparticles by a collection medium.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: December 29, 2020
    Inventors: David S. Ensor, Howard Jerome Walls, Karin K. Foarde, Susanne Vera Hering, Steven Russel Spielman
  • Patent number: 10876146
    Abstract: Method for detecting the presence of nucleases in a sample, characterized in that it comprises the steps of: —incubating the sample to be tested for the presence of nucleases with at least one oligonucleotide linker constituting the substrate for the nuclease to be detected, for a sufficient time to cause degradation of said oligonucleotide linker by the nuclease possibly present in the sample, —adding to the sample, upon incubation, colloidal gold nanoparticles comprising gold nanoparticles functionalized with a first probe oligonucleotide and gold nanoparticles functionalized with a respective second probe oligonucleotide, said first and second probe oligonucleotides being complementary to a respective portion of the nucleotide sequence of the oligonucleotide linker, and—examining the possible colour change of the sample as a result of the addition of said nanoparticles, a colour change of the sample to the colour assumed by the colloidal gold particles when aggregated at a distance less than their size bei
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 29, 2020
    Assignee: Fondazione Istituto Italiano di Tecnología
    Inventors: Pier Paolo Pompa, Paola Valentini, Paola Cecere
  • Patent number: 10876147
    Abstract: The present disclosure provides methods of generating supports (e.g., beads) comprising barcode molecules coupled thereto. A barcode molecule coupled to a support may comprise a barcode sequence and a functional sequence. A barcode molecule may be generated using two or more ligation reactions in a combinatorial fashion. A support comprising two or more different barcode molecules may be useful for analyzing or processing one or more analytes such as nucleic acid molecules, proteins, and/or perturbation agents.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: December 29, 2020
    Assignee: 10X GENOMICS, INC.
    Inventors: Zachary Bent, Elliott Meer, Daniel Riordan, Paul Ryvkin, Niranjan Srinivas, Jessica Terry
  • Patent number: 10876148
    Abstract: Methods and formulations for preparing low non-specific binding surfaces are described, and the prepared surface can provide improved performance for nucleic acid detection and base calling applications. The surface provides more accurate nucleic acid detection, enhanced contrast to noise ratio, and better data collection.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 29, 2020
    Assignee: ELEMENT BIOSCIENCES, INC.
    Inventors: Chunhong Zhou, Sinan Arslan, Molly Min He, Matthew Kellinger, Adeline Huizhen Mah, Michael Previte, Lei Sun
  • Patent number: 10876149
    Abstract: The present invention provides methods for detecting a target nucleic acid in a sample by, for example, incubating the target nucleic acid with a detection probe containing a nucleic acid sequence complementary to at least a portion of the target nucleic acid and a nuclease enzyme that specifically cleaves double-stranded nucleic acids. Hybridization between the detection probe and the target nucleic acid thereby leads to cleavage of the detection probe, releasing a portion of the probe attached to a detectable agent. The portions of the digested probes attached to the detectable agent can be separated from unbound probe and detected in order to determine the presence of the target nucleic acid in the sample. Thus, the invention enables rapid and accurate analysis of a sample for the presence of desired nucleic acid biomarkers.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: December 29, 2020
    Assignee: Prominex, Inc.
    Inventor: Michael McClellan Becker
  • Patent number: 10876150
    Abstract: Gold nanorattle probes are provided that are highly tunable, physiologically stable, and ultra-bright Raman probes for in vitro and in vivo surface-enhanced Raman scattering (SERS) applications. The nanorattles contain an essentially uniform gap between core and shell that is tunable and can range from 2 nm to 10 nm in width. This provides numerous advantages including allowing for increased loading with a variety of dye molecules that exhibit SERS in various spectral regions, including the “tissue optical window” for in vivo studies. In addition, the nanorattle probes provide an internal label when used in diagnostic methods to detect nucleic acids, proteins and other biotargets. The nanorattles have an essentially spherical gold metal nanoparticle core, a porous material of silver metal of an essentially uniform width surrounding the nanoparticle core that is loaded with one or more SERS reporter molecules, and an outer gold metal shell encapsulating the porous material.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: December 29, 2020
    Assignee: Duke University
    Inventors: Tuan Vo-Dinh, Naveen Gandra, Hoan T. Ngo
  • Patent number: 10876151
    Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: December 29, 2020
    Assignee: The General Hospital Corporation
    Inventors: Tilak K. Sundaresan, Zongli Zheng, Daniel A. Haber, Shyamala Maheswaran, A. John Iafrate
  • Patent number: 10876152
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: December 29, 2020
    Assignee: GUARDANT HEALTH, INC.
    Inventors: AmirAli Talasaz, Stefanie Ann Ward Mortimer
  • Patent number: 10876153
    Abstract: The nucleic acid detection method includes maintaining a reaction liquid containing the sample, a marker substance, polymerase, a primer set, and salt of a predetermined concentration in the reaction field which include a substrate and a probe, under an amplification condition, detecting a signal from the marker substance and determining existence and/or quantity of the target nucleic acid. The predetermined concentration is higher than the concentration in which the peak rate of the amplification reaction and the concentration with which the hybridization rate becomes higher than 0 au, whichever is higher, but not greater than the highest one of the concentrations with which the quantity of detection of the amplification product becomes a threshold value or more.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: December 29, 2020
    Assignee: Kabushiki Kaisha Toshiba
    Inventors: Koji Hashimoto, Keiko Ito
  • Patent number: 10876155
    Abstract: The present invention relates to differentiating signals of interest for target nucleic acid sequences. The present invention permits to obtain an individual signal value (i.e., variable) contained in a total signal detected at detection temperatures by using mathematical equations. The present invention based on equation-solving approach enables to obtain the individual signal value in a systematical manner, thereby providing analysis results in much more accurate and convenient manner.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: December 29, 2020
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, Young Jo Lee
  • Patent number: 10876156
    Abstract: The present invention generally relates to microfluidics and, in particular, to systems and methods for determining cells using amplification. In one set of embodiments, cells are encapsulated within droplets and nucleic acids from the cells amplified within the droplets. The droplets may then be pooled together and the amplified nucleic acids can be determined using PCR or other suitable techniques. In some embodiments, techniques such as these can be used to detect relatively rare cells that may be present, e.g., if the droplets are amplified using conditions able to selectively amplify nucleic acids arising from the relatively rare cells.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: December 29, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Weitz, Huidan Zhang
  • Patent number: 10876157
    Abstract: Disclosed are insulated nanoelectrode associated with nanopores, useful in macromolecular analysis devices. Also disclosed are related methods of fabrication and use.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: December 29, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Marija Drndic, Ken Healy, Vishva Ray, Lauren J. Willis, Neil Peterman, John Bartel
  • Patent number: 10876158
    Abstract: The invention provides methods for pairwise sequencing of a double-stranded polynucleotide template, which methods result in the sequential determination of nucleotide sequences in two distinct and separate regions of the polynucleotide template.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: December 29, 2020
    Assignee: Illumina Cambridge Limited
    Inventors: Geoffrey Paul Smith, Jonathan Mark Boutell, Colin Lloyd Barnes, Roberto Rigatti, Niall Anthony Gormley, David Bentley, Tobias William Barr Ost, Vincent Peter Smith, Graham John Worsley, Eric Hans Vermaas
  • Patent number: 10876159
    Abstract: The present invention provides technology that uses current measurements to identify nucleotides and determine a nucleotide sequence in polynucleotides. The present invention calculates a modal value of a tunnel current that arises when a nucleotide or polynucleotide for analysis passes through between electrodes, and then employs the calculated modal value. The present invention accordingly enables direct rapid implementation to identify nucleotides and to determine a nucleotide sequence in a polynucleotide without marking.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 29, 2020
    Assignee: QUANTUM BIOSYSTEMS INC.
    Inventors: Masateru Taniguchi, Makusu Tsutsui, Kazumichi Yokota, Tomoji Kawai
  • Patent number: 10876160
    Abstract: The purpose of the present invention is to provide: a novel method for detecting a target nucleic acid; and a kit for use in the method. In the detection method according to the present invention, a fluorophore-labeled primer/probe and a quencher-labeled probe, which have complementarity to each other, are so designed as to have different melting temperatures (Tm) from each other so that the fluorophore-labeled primer can anneal preferentially to the target nucleic acid. The detection method is so designed that the fluorophore-labeled primer/probe that is not bound to the target nucleic acid is bound to the quenching probe so as to emit no fluorescence. The method enables the detection of the target nucleic acid in a simpler manner, at lower cost, and without requiring the use of any technique or device.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: December 29, 2020
    Assignee: Eiken Kagaku Kabushiki Kaisha
    Inventors: Norimitsu Hosaka, Satoshi Higashide
  • Patent number: 10876161
    Abstract: The present invention encompasses methods and kits employing pattern recognition receptor expression as a measure of systemic health in a subject afflicted with an oral health condition. In particular, the present invention is directed to methods involving measurement of the expression levels of one or more Pattern Recognition Receptors including but not limited to Toll Like Receptors, myeloid differentiation primary response gene 88 (MyD88), and Nucleotide Binding oligomerization domain containing protein 1 (NOD1), in a companion animal, e.g., a dog or a cat, afflicted with an oral health condition. The described methods enable evaluation of the systemic health of the animal afflicted with an oral health condition by measuring expression levels of the indicated genes as compared to suitable controls.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 29, 2020
    Assignee: Hills Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Dale S. Scherl
  • Patent number: 10876162
    Abstract: The present invention provide methods using genes associated with multi-drug resistance for rapidly detecting a patient colonized or infected with an multi-drug resistant organism and administrating the appropriate precautions and/or treatment.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: December 29, 2020
    Assignee: OPGEN, INC.
    Inventors: George Terrance Walker, Tony Rockweiler, Alex Saeed, Vadim Sapiro, Rossio Kersey
  • Patent number: 10876163
    Abstract: The present invention relates to a method, in particular an in vitro method for identifying FoxP3-positive regulatory T cells, preferably CD25+CD4+ regulatory T cells of a mammal, comprising analysing the methylation status of at least one CpG position in the gene foxp3 or an orthologous or paralogous gene thereof, and the use of DNA-methylation analysis of the gene of the transcription factor FoxP3 for a detection and quality assurance and control of regulatory T cells. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: December 29, 2020
    Assignees: Epiontis GmbH, Charite-Universitatsmedizin Berlin
    Inventors: Jochen Huehn, Stefan Floess, Alf Hamann, Sven Olek, Udo Baron
  • Patent number: 10876164
    Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 29, 2020
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
  • Patent number: 10876165
    Abstract: The present invention relates to the field of detection of colorectal cancer (CRC). Specifically it relates to methods for the early detection, risk screening and monitoring of CRC and/or adenomatous polyps in a human subject based on the quantification of one or more 16S rDNA bacterial sequences in feces. It further relates to the use of said bacterial sequences as biomarkers of colorectal cancer and/or adenomatous polyps; to a kit comprising a reagent and instructions for the quantification of said bacterial sequences; and to nucleic acids for the quantification of said 16S rDNA bacterial sequences.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: December 29, 2020
    Inventors: Mariona Serra Pagès, Librado Jesús García-Gil, Teresa Mas De Xaxars, Xavier Aldeguer Manté
  • Patent number: 10876166
    Abstract: A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: December 29, 2020
    Assignee: Andes Biotechnologies Global, Inc.
    Inventors: Luis O. Burzio, Jaime E. Villegas, Veronica A. Burzio
  • Patent number: 10876167
    Abstract: A biomarker panel of 12 genes based on expression levels. Methods for calculating prognostic scores and patient ranking based on their score and divided into two equal sized cohorts. Kaplan-Meier analysis and a log-rank test were used to determine differences in survival.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: December 29, 2020
    Assignee: The Regents of the University of California
    Inventors: Antoine M. Snijders, Xuan Yu Mao, Matthew J. Lee
  • Patent number: 10876168
    Abstract: The present invention discloses a tumor molecular detection/diagnostic reagent, which takes excrement as a detection sample and includes an SDC2 gene methylation detection reagent. The methylation level of the SDC2 gene detected in the excrement has an extremely high relevance to the onset of the colorectal cancer. The sensitivity of the SDC2 gene in the excrement is 87 percent and the specificity is up to 98 percent or even higher than that in tissue.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 29, 2020
    Assignee: CREATIVE BIOSCIENCES (GUANGZHOU) CO., LTD.
    Inventors: Hongzhi Zou, Feng Niu, Shan Wu, Rongsong Zhao, Hao Yu
  • Patent number: 10876169
    Abstract: A method of estimating the amount of a methylated locus is provided. In certain embodiments the method comprises: digesting a nucleic acid sample that contains both unmethylated and methylated copies of a genomic locus with an MspJI family member to produce a population of fragments that are in the range of 20-40 nucleotides in length, ligating adaptor sequence A and adaptor sequence B to the respective ends of a target fragment of sequence X, and quantifying the amount of ligation products of formula A-X-B. A kit for performing the method is also provided.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: December 29, 2020
    Assignee: VANADIS DIAGNOSTICS
    Inventors: Carl Oscar Fredrik Dahl, Olof John Ericsson, Johan Banér
  • Patent number: 10876170
    Abstract: The present disclosure relates to methods for detecting and targeting genomic rearrangements, in particular gene fusion events, by targeting a DNA molecule of interest with a set or pool of primers, wherein the forward primers and reverse primers produce a PCR amplification product when a genomic rearrangement is present. The present disclosure also relates to methods of bioinformatic analysis to determine whether or not the detection of an amplification product from the selective PCR is actually indicative of the presence of a gene fusion. The present disclosure also related to related methods of diagnosis and treatment of diseases and conditions associated with such genomic rearrangements, in particular cancers, such as lung cancer.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 29, 2020
    Assignee: INIVATA LTD.
    Inventors: Samuel Woodhouse, Stefanie Lensing, Tim Forshew, Vincent Plagnol, Matthew Edward Smith, Karen Howarth, Michael Epstein
  • Patent number: 10876171
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: December 29, 2020
    Assignee: GUARDANT HEALTH, INC.
    Inventor: AmirAli Talasaz
  • Patent number: 10876172
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: December 29, 2020
    Assignee: GUARDANT HEALTH, INC.
    Inventor: AmirAli Talasaz
  • Patent number: 10876173
    Abstract: An assay kit of reagents including a nucleic acid capable of acting as substrate for polymerase microorganism activity useful in a method of detecting polymerase activity as an indicator of the presence of a micro-organism in a sample are disclosed. The disclosed embodiments also relate to reagents for use in such methods, and to test kits comprising such reagents for carrying out the methods.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: December 29, 2020
    Inventors: Shawn Mark O'Hara, Daniel Zweitzig
  • Patent number: 10876174
    Abstract: The invention relates to a cartridge for the detection and characterization of a toxinogenic Clostridium difficile strain in a sample, wherein the following steps are performed, (i) a sample is provided for, (ii) in a multiplex PCR assay, (iii) the sample is analyzed with respect to the presence or absence of the cytotoxin tcdB gene, (iv) the sample is analyzed with respect to the presence or absence of one or more of the following deletions in the tcdC gene: (a) an 18 bp deletion in SEQ ID NO. 1 from nucleotide 330 to nucleotide 347, (b) a 36 bp deletion in SEQ ID NO. 1 from nucleotide 301 to nucleotide 336, (c) a 39 bp deletion in SEQ ID NO. 1 from nucleotide 341 to nucleotide 370, (d) a 54 bp deletion in SEQ ID NO. 1 from nucleotide 313 to nucleotide 366 and (e) a single nucleotide deletion at position 117 of SEQ ID NO. 1. The invention also relates to respective kits and primers and probes.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 29, 2020
    Assignee: Koninklijke Philips N.V.
    Inventors: Patrick Theodoor Christian van den Bogaard, Astrid Elisabeth Visser
  • Patent number: 10876175
    Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotide.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: December 29, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Edgar Ong, Maurice Exner
  • Patent number: 10876176
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 29, 2020
    Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • Patent number: 10876177
    Abstract: Provided are methods and compositions relating to conjugation of nucleic acids and proteins of interest under conditions that maintain protein activity. The nucleic acid-protein conjugates may be used in nucleic acid nanostructures such as those generated using DNA origami methods.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: December 29, 2020
    Assignees: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Mounir Ahmad Koussa, Wesley Philip Wong
  • Patent number: 10876178
    Abstract: Processes for converting lignocellulose to feedstock and downstream products are disclosed. The processes may include acid treatment of lignocellulose to produce a fermentation feedstock. In various instances, the processes include recovery or recycling of acid, such as recovery of hydrochloric acid from concentrated and/or dilute streams. Downstream products may include acrylic acid-based products such as diapers, paper and paper-based products, ethanol, biofuels such as biodiesel and fuel additives, and detergents.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 29, 2020
    Assignee: Virdia, Inc.
    Inventors: Aharon Eyal, Robert P. Jansen
  • Patent number: 10876179
    Abstract: A method is provided for producing a hot-formed component, in particular a sheet-metal component made of steel, aluminum, magnesium or a combination of the materials. The method includes the acts of: heating a semifinished product, in particular a sheet-metal blank or a pre-shaped sheet-metal component, inserting the semifinished product into a molding tool, and quenching the semifinished product in the molding tool, wherein a change is made to the microstructure of the material at least in one portion. Before the insertion of the semifinished product into the molding tool, an insulating device is applied in at least one predetermined region of the semifinished product. The insulating device is connected in a form-fitting, integral and/or force-fitting manner to the semifinished product.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 29, 2020
    Assignee: Bayerische Motoren Werke Aktiengesellschaft
    Inventors: Bernd Kupetz, Juergen Becker
  • Patent number: 10876180
    Abstract: A method of manufacturing a hot rolled steel sheet for a square column for building structural members includes a hot rolling step, a cooling step, and a coiling step performed on a steel to form a hot rolled steel sheet, wherein the steel has a composition containing, in terms of % by mass, C: 0.07 to 0.18%, Mn: 0.3 to 1.5%, P: 0.03% or less, S: 0.015% or less, Al: 0.01 to 0.06%, N: 0.0006% or less, and the balance being Fe and unavoidable impurities.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: December 29, 2020
    Assignee: JFE Steel Corporation
    Inventors: Chikara Kami, Yuta Tamura, Takato Tamai, Shuji Kawamura
  • Patent number: 10876181
    Abstract: In a cold-rolled steel sheet having a predetermined chemical composition, a metallographic structure contains 40.0% or more and less than 60.0% of a polygonal ferrite, 30.0% or more of a bainitic ferrite, 10.0% to 25.0% of a residual austenite, and 15.0% or less of a martensite, by an area ratio, in the residual austenite, a proportion of the residual austenite in which an aspect ratio is 2.0 or less, a length of a long axis is 1.0 ?m or less, and a length of a short axis is 1.0 ?m or less, is 80.0% or more, in the bainitic ferrite, a proportion of the bainitic ferrite in which an aspect ratio is 1.7 or less and an average value of a crystal orientation difference in a region surrounded by a boundary in which a crystal orientation difference is 15° or more is 0.5° or more and less than 3.0°, is 80.0% or more, and a connection index D value of the martensite, the bainitic ferrite, and the residual austenite is 0.70 or less.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: December 29, 2020
    Assignee: NIPPON STEEL CORPORATION
    Inventors: Kengo Takeda, Kunio Hayashi, Akihiro Uenishi, Masafumi Azuma, Takayuki Nozaki, Yuri Toda